Literature DB >> 20380624

Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers.

Neeraj K Garg1, Sharad Mangal, Hemant Khambete, Pradeep K Sharma, Rajeev K Tyagi.   

Abstract

Majority of infectious microorganism make their gateway to the host through mucosal surfaces, such as gastrointestinal tract, nasal and vaginal tract. Mucosal immune response structured as sIgA can effectively prevent the attachment and invasion of the microorganism from mucosal surface and thereby serves as an efficient tool against infectious disease. There has been an increased demand for the development of novel vaccine that leads to the induction of immune response in systemic circulation as well as at mucosal surfaces against infectious disease. Mucosal delivery of vaccine provides basis for induction of both mucosal as well as systemic immune responses against the infectious organisms. However, a variety of factors such as mucociliary clearance, presence of deteriorating enzymes, pH extremes (GIT), low permeation and metabolic degradation limit the mucosal delivery of vaccine. Numerous strategies have been explored in the meadow of mucosal vaccination for the purpose of efficient antigen delivery through mucosal route(s). Polymeric carrier(s) such as nanoparticles and microparticles loaded with the antigen can serve as the basis for creation of important formulations for improved vaccine. Biodegradable and mucoadhesive polymeric carrier(s) seems to be most promising candidate for mucosal vaccine delivery. Several polymers from natural and synthetic origin, such as polylactide-co-glycolide, chitosan, alginate, carbopol, gelatin etc., have been explored for the efficient mucosal vaccine delivery and significant results have been obtained. This review outlines the polymers used in mucosal vaccine delivery with special reference to mucoadhesive/biodegradable polymers. This article also covers the recent patent granted in the field on polymeric carrier mediated mucosal vaccination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20380624     DOI: 10.2174/187221110791185015

Source DB:  PubMed          Journal:  Recent Pat Drug Deliv Formul        ISSN: 1872-2113


  20 in total

1.  Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis.

Authors:  Arianne L Theiss; Hamed Laroui; Tracy S Obertone; Indrajit Chowdhury; Winston E Thompson; Didier Merlin; Shanthi V Sitaraman
Journal:  Inflamm Bowel Dis       Date:  2010-09-24       Impact factor: 5.325

Review 2.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

3.  Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Karin Hartog; Jonathan L Heeney; David Montefiori; Indresh K Srivastava; Susan W Barnett
Journal:  Vaccine       Date:  2012-02-22       Impact factor: 3.641

Review 4.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

Review 5.  Intranasal immunization with dry powder vaccines.

Authors:  Tania F Bahamondez-Canas; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2017-11-06       Impact factor: 5.571

6.  Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization.

Authors:  Morteza Abkar; Abbas Sahebghadam Lotfi; Jafar Amani; Khadijeh Eskandari; Mehdi Fasihi Ramandi; Jafar Salimian; Gholamreza Nikbakht Brujeni; Saeed Alamian; Mehdi Kamali; Hamid Koushki
Journal:  Vet Res Commun       Date:  2015-09-22       Impact factor: 2.459

7.  Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.

Authors:  Lissette S Velasquez; Samantha Shira; Alice N Berta; Jacquelyn Kilbourne; Babu M Medi; Ian Tizard; Yawei Ni; Charles J Arntzen; Melissa M Herbst-Kralovetz
Journal:  Vaccine       Date:  2011-06-02       Impact factor: 3.641

8.  Development of enhanced antibody response toward dual delivery of nano-adjuvant adsorbed human Enterovirus-71 vaccine encapsulated carrier.

Authors:  Mohamed I Saeed; Abdul Rahman Omar; Mohd Z Hussein; Isam M Elkhidir; Zamberi Sekawi
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.

Authors:  Dharmendra Raghuwanshi; Vivek Mishra; Dipankar Das; Kamaljit Kaur; Mavanur R Suresh
Journal:  Mol Pharm       Date:  2012-03-20       Impact factor: 4.939

10.  Immunological Assessment of Chitosan or Trimethyl Chitosan-Coated PLGA Nanospheres Containing Fusion Antigen as the Novel Vaccine Candidates Against Tuberculosis.

Authors:  Sirwan Zare; Mona Kabiri; Yousef Amini; Adel Najafi; Fatemeh Mohammadpour; Seyed Hasan Ayati; Amin Reza Nikpoor; Mohsen Tafaghodi
Journal:  AAPS PharmSciTech       Date:  2021-12-10       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.